Clinical trial
A Multi-Center, Randomized, Double-Blind, Active-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease
NCT03736369 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Double-Blind, Active-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 13, 2018
- Completion date
- August 7, 2019
- Enrollment
- 263 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
erosive esophagitis